184 related articles for article (PubMed ID: 32615624)
21. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma.
Tesfaye AA; Philip PA
Clin Adv Hematol Oncol; 2019 Jan; 17(1):54-63. PubMed ID: 30843899
[TBL] [Abstract][Full Text] [Related]
22. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
23. Pancreas-protocol imaging at a high-volume center leads to improved preoperative staging of pancreatic ductal adenocarcinoma.
Walters DM; Lapar DJ; de Lange EE; Sarti M; Stokes JB; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Oct; 18(10):2764-71. PubMed ID: 21484522
[TBL] [Abstract][Full Text] [Related]
24. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
25. Modified Appleby procedure for borderline resectable/locally advanced distal pancreatic adenocarcinoma: A major procedure for selected patients.
Cesaretti M; Abdel-Rehim M; Barbier L; Dokmak S; Hammel P; Sauvanet A
J Visc Surg; 2016 Jun; 153(3):173-81. PubMed ID: 26775202
[TBL] [Abstract][Full Text] [Related]
26. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
27. What is the Value of Total Mesopancreas Excision in Pancreatic Ductal Adenocarcinoma? Current Evidence of the Literature.
Popescu I; Dumitrascu T
Chirurgia (Bucur); 2018; 113(3):335-343. PubMed ID: 29981664
[TBL] [Abstract][Full Text] [Related]
28. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery.
Ariake K; Mizuma M; Motoi F; Maeda S; Morikawa T; Ishida M; Ohtsuka H; Aoki S; Miura T; Takadate T; Nakagawa K; Kamei T; Unno M
Ann Surg Oncol; 2021 Oct; 28(11):6246-6254. PubMed ID: 33611747
[TBL] [Abstract][Full Text] [Related]
29. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.
Ruess DA; Makowiec F; Chikhladze S; Sick O; Riediger H; Hopt UT; Wittel UA
BMC Surg; 2015 Nov; 15():123. PubMed ID: 26615588
[TBL] [Abstract][Full Text] [Related]
30. Second pancreatectomy for recurrent pancreatic ductal adenocarcinoma in the remnant pancreas: A pooled analysis.
Zhou Y; Song A; Wu L; Si X; Li Y
Pancreatology; 2016; 16(6):1124-1128. PubMed ID: 27717684
[TBL] [Abstract][Full Text] [Related]
31. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature.
Zhou Y; Liao S; You J; Wu H
Updates Surg; 2022 Feb; 74(1):43-53. PubMed ID: 34021484
[TBL] [Abstract][Full Text] [Related]
32. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
33. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection.
Yang J; Zhang J; Lui W; Huo Y; Fu X; Yang M; Hua R; Wang L; Sun Y
HPB (Oxford); 2020 Jan; 22(1):91-101. PubMed ID: 31262486
[TBL] [Abstract][Full Text] [Related]
34. Ten years of experience with resection of left-sided pancreatic ductal adenocarcinoma: evolution and initial experience to a laparoscopic approach.
Kang CM; Kim DH; Lee WJ
Surg Endosc; 2010 Jul; 24(7):1533-41. PubMed ID: 20054579
[TBL] [Abstract][Full Text] [Related]
35. Effect of time to surgery in resectable pancreatic cancer: a systematic review and meta-analysis.
Müller PC; Hodson J; Kuemmerli C; Kalisvaart M; Pande R; Roberts KJ
Langenbecks Arch Surg; 2020 May; 405(3):293-302. PubMed ID: 32447457
[TBL] [Abstract][Full Text] [Related]
36. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma.
Sakaguchi T; Satoi S; Yamamoto T; Yamaki S; Sekimoto M
Surg Today; 2020 Apr; 50(4):335-343. PubMed ID: 31993761
[TBL] [Abstract][Full Text] [Related]
37. Laparoscopic distal pancreatosplenectomy for pancreatic ductal adenocarcinoma.
Kuroki T; Eguchi S
Surg Today; 2015 Jul; 45(7):808-12. PubMed ID: 25156008
[TBL] [Abstract][Full Text] [Related]
38. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer.
Hartwig W; Gluth A; Hinz U; Koliogiannis D; Strobel O; Hackert T; Werner J; Büchler MW
Br J Surg; 2016 Nov; 103(12):1683-1694. PubMed ID: 27686238
[TBL] [Abstract][Full Text] [Related]
39. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis.
Lindemann J; du Toit L; Kotze U; Bernon M; Krige J; Jonas E
HPB (Oxford); 2021 Feb; 23(2):173-186. PubMed ID: 33268268
[TBL] [Abstract][Full Text] [Related]
40. Vascular Resections for Pancreatic Ductal Adenocarcinoma: Vascular Resections for PDAC.
Oba A; Bao QR; Barnett CC; Al-Musawi MH; Croce C; Schulick RD; Del Chiaro M
Scand J Surg; 2020 Mar; 109(1):18-28. PubMed ID: 31960765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
